- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02803268
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
February 9, 2017 updated by: Mitsubishi Tanabe Pharma Corporation
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
City name, Germany
- Investigational center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subjects must meet one of the following criteria:Woman aged ≥18 years with histologically proven non-metastatic breast cancer (Stages I, II or III) and without evidence of disease / Woman aged ≥40 years who are post-menopausal / Woman aged ≥40 years who are peri-menopausal
- Subjects who have ≥7 Vasomotor Symptoms per day on average
- A body weight of ≥45 kg
Exclusion Criteria:
- Participation in more than three clinical studies involving administration of an unlicensed Investigational Medicinal Product in the previous year, or any study within 12 weeks
- Clinically significant endocrine, thyroid, hepatic, respiratory, gastro-intestinal, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder
- Clinically relevant abnormal medical history, physical findings or laboratory values
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MT-8554 low dose
Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.
|
|
EXPERIMENTAL: MT-8554 middle dose
Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.
|
|
EXPERIMENTAL: MT-8554 high dose
Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and Tolerability as measured by vital signs
Time Frame: Up to Day 21
|
Up to Day 21
|
Safety and Tolerability as measured by number of participants with adverse events
Time Frame: Up to Day 21
|
Up to Day 21
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentration of MT-8554 after dosing
Time Frame: Up to Day 15
|
Up to Day 15
|
Change from baseline in core body temperature
Time Frame: Up to Day 14
|
Up to Day 14
|
Frequency of Vasomotor Symptoms
Time Frame: Up to Day 15
|
Up to Day 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2016
Primary Completion (ACTUAL)
January 1, 2017
Study Completion (ACTUAL)
January 1, 2017
Study Registration Dates
First Submitted
June 14, 2016
First Submitted That Met QC Criteria
June 14, 2016
First Posted (ESTIMATE)
June 16, 2016
Study Record Updates
Last Update Posted (ACTUAL)
February 13, 2017
Last Update Submitted That Met QC Criteria
February 9, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- MT-8554-E04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasomotor Symptoms
-
Hansoh BioMedical R&D CompanyRecruiting
-
BayerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVasomotor SymptomsMexico
-
Mitsubishi Tanabe Pharma America Inc.CompletedVasomotor Symptoms (VMS)United States
-
Duramed ResearchCompletedNocturnal Vasomotor SymptomsUnited States
-
BayerCompletedVasomotor SymptomsKorea, Republic of
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; Spaulding Rehabilitation HospitalWithdrawnVasomotor Symptoms | Cardiovascular HealthUnited States
-
PfizerCompletedVasomotor SymptomsCanada, United States
-
Changchun GeneScience Pharmaceutical Co., Ltd.Syneos HealthRecruitingVasomotor Symptoms | Adult Healthy VolunteersAustralia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States